What did FDA actually approve for ZILBRYSQ, and what evidence supported the autoinjector?
Peptide Info Hexarelin Peptide The approval rested on three study types, and each answers a different question. The Phase 3b usability data in UCB’s announcement report complete dose delivery for 99.8% (n=449) of autoinjector administrations, where the denominator is total autoinjectors used and returned, not patients (UCB’s approval announcement).
The human factors validation study enrolled 100 participants across patients, caregivers and health care professionals, そして 90% completed an injection on the first attempt without training (UCB’s approval announcement). The bioequivalence study described in the release, DV0012, was a two-period crossover in 14 healthy adults; the release states bioequivalence was established but publishes no AUC or Cmax ratios.
What is not public matters as much: the autoinjector’s container-closure materials, its extractables and leachables package, and its container closure integrity data are absent from both the release and the label.
重要なポイント A device supplement adds an administration option on the same molecule and indication. A formulation change alters the drug product itself. The two carry different evidence burdens, and only the second typically reopens the drug-substance specification.
Why isn’t a validated sequence and purity specification enough to launch a device-delivered peptide?
Peptide delivery readiness is a property of the drug product in its container and device, not of the drug substance certificate. A specification is a narrow control by design. I Q6B defines Humanin Peptide it as a list of tests, analytical procedures and acceptance criteria proposed by the manufacturer. It confirms quality; it does not establish full characterization. 米国薬局 <1503> gives synthetic peptides the same shape: appearance, 直交手法による同一性, assay, impurities and specific tests.
None of that describes how the molecule behaves when a spring pushes it through a 29-gauge needle. FDAの ペプチド製品工場 2026 draft container-closure guidance names piston syringes among container closure systems that are also device constituent parts. It expects glide force, break-loose force and seal integrity testing.
The product has several fill volumes and strengths. Verify the approved presentation and device configuration for each; differing volumes do not prove that a single interchangeable device can handle every presentation.
Treating device evidence as optional has a documented cost. FDA’s complete response letters for Remodulin state that “sufficient human factors (HF) data has not been provided to demonstrate that the … user interface supports safe and effective use.”
How do concentration, dose volume, viscosity and container contact decide whether a device format is feasible?
Device performance depends on volume, viscosity, needle geometry, force, temperature and formulation together. Examples using different needles cannot isolate viscosity’s effect. Set requirements using the applicable device standard and configuration rather than a universal volume or 10 N limit. Antimicrobial Peptides
<図形クラス="ブログチャート" スタイル="最大幅:640ピクセル;マージン:1.5レムオート;フォントサイズ:12ピクセル;行の高さ:1.3;色:継承する"> <svg viewBox="0 0 560 380" スタイル="最大幅: 100%; 身長: 自動; フォントファミリー: 「インター」, システムUI, サンセリフ; 色: #1e293b; --チャートミュート: #64748b;" 役割="画像" aria-labeledby="zilbrysq-dose-volume-by-weight-band-title zilbrysq-dose-volume-by-weight-band-desc"> <スタイル> /* レンダラは、要素の背景が黒の iframe にグラフを配置します。, iframe はチャートとは異なる形状です, そのため、レターボックスのバンドが周囲の黒い枠として表示されました (プロッド 09-22). iframe 内のドキュメントはデフォルトで透明です; ここにペイントすると要素の背景がカバーされます, 代わりにチャートがインライン化されている場合、これは何も一致しません. このブロックには山かっこを入れないでください: SVG 内のスタイル要素は外部コンテンツとして解析されます, したがって、1 つの浮遊括弧はその中のすべてのルールを破棄します. */ html, 体 { 背景: #ふふふふ; マージン: 0; } @メディア (縮小モーションを好む: 減らす) { * { アニメーション: なし !重要; 遷移: なし !重要; } } </スタイル> <長方形 x="0" y="0" 幅="560" 身長="380" rx="8" 塗りつぶし="#ふふふふ" /> <タイトルID="zilbrysq-dose-volume-by-weight-band-title">ZILBRYSQ dose volume by weight band</タイトル> <説明ID="zilbrysq-dose-volume-by-weight-band-desc">The three approved strengths deliver 0.416, 0.574 そして 0.81 mL per once-daily subcutaneous dose. ZILBRYSQ dose volume by weight band. 横棒データ: <56 kg 0.416; 56 に <77 kg 0.574; ≥77 kg 0.81.Source: ZILBRYSQ prescribing information 2023.</説明> <テキストx="280.0" y="29" テキストアンカー="真ん中" フォントサイズ="18" フォントの太さ="800" 塗りつぶし="現在の色">ZILBRYSQ dose volume by weight band</文章> <行 x1="145" y1="298.0" x2="510" y2="298.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="243.0" x2="510" y2="243.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="188.0" x2="510" y2="188.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="133.0" x2="510" y2="133.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="78.0" x2="510" y2="78.0" ストローク="現在の色" 不透明度="0.08" /> <テキストx="136.0" y="122.2" テキストアンカー="終わり" フォントサイズ="11" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="136.0" ディ="0"><56 kg</ツパン></文章> <長方形 x="145" y="78.0" 幅="151.8" 身長="68.0" rx="4" 塗りつぶし="#f97316" /> <テキストx="304.8" y="122.2" フォントサイズ="11" 塗りつぶし="現在の色">0.416</文章> <テキストx="136.0" y="198.2" テキストアンカー="終わり" フォントサイズ="11" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="136.0" ディ="0">56 に <77 kg</ツパン></文章> <長方形 x="145" y="154.0" 幅="209.5" 身長="68.0" rx="4" 塗りつぶし="#38bdf8" /> <テキストx="362.5" y="198.2" フォントサイズ="11" 塗りつぶし="現在の色">0.574</文章> <テキストx="136.0" y="274.2" テキストアンカー="終わり" フォントサイズ="11" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="136.0" ディ="0">≥77 kg</ツパン></文章> <長方形 x="145" y="230.0" 幅="295.7" 身長="68.0" rx="4" 塗りつぶし="#a78bfa" /> <テキストx="448.7" y="274.2" フォントサイズ="11" 塗りつぶし="現在の色">0.81</文章> <テキストx="280.0" y="366" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="私たちの(--チャートミュート, 現在の色)">ソース: ZILBRYSQ prescribing information (2023)</文章> </SVG> </形>
Container contact is where the peptide certificate stops. In the epoetin alfa prefilled-syringe case, two batches filled from the same solution differed only in fill volume, and individual syringes aggregated up to 5.1% そして 1.5%, with soluble tungsten averaging about 1 ppm and reaching 4 ppm in individual syringes (Seidl et al. in Pharmaceutical Research). Published tungsten precipitation data show the threshold moving from about 3 ppm at pH 5.0 to no precipitation above 200 ppm at pH 6.0 (Bee et al. in the Journal of Pharmaceutical Sciences). Silicone oil and tungsten are container extractables, not peptide attributes, so peptide container closure compatibility cannot be certified by the substance supplier.
Extractables and leachables have their own framework and thresholds. 米国薬局 <1663> そして <1664> set the assessment structure, while the PQRI parenteral E&L thresholds place a 1.5 µg/day safety concern threshold and a 5 µg/day qualification threshold per individual organic leachable (米国薬局; PQRI). The draft ICH Q3E guideline, at Step 2 since August 2025, extends scope to drug-device combination products with implementation anticipated by June 2027 (ICH Q3E Step 2 presentation).
What should I demand from my peptide partner versus my device partner before locking a format?
Lock a device format only after the drug-substance package, the formulation attributes and the container’s extractable profile have been assessed together. That makes peptide delivery readiness a joint decision, not a handoff.
<図形クラス="ブログチャート" スタイル="最大幅:640ピクセル;マージン:1.5レムオート;フォントサイズ:12ピクセル;行の高さ:1.3;色:継承する"> <svg viewBox="0 0 560 380" スタイル="最大幅: 100%; 身長: 自動; フォントファミリー: 「インター」, システムUI, サンセリフ; 色: #1e293b; --チャートミュート: #64748b;" 役割="画像" aria-labeledby="parenteral-leachable-thresholds-title parenteral-leachable-thresholds-desc"> <スタイル> /* レンダラは、要素の背景が黒の iframe にグラフを配置します。, iframe はチャートとは異なる形状です, そのため、レターボックスのバンドが周囲の黒い枠として表示されました (プロッド 09-22). iframe 内のドキュメントはデフォルトで透明です; ここにペイントすると要素の背景がカバーされます, 代わりにチャートがインライン化されている場合、これは何も一致しません. このブロックには山かっこを入れないでください: SVG 内のスタイル要素は外部コンテンツとして解析されます, したがって、1 つの浮遊括弧はその中のすべてのルールを破棄します. */ html, 体 { 背景: #ふふふふ; マージン: 0; } @メディア (縮小モーションを好む: 減らす) { * { アニメーション: なし !重要; 遷移: なし !重要; } } </スタイル> <長方形 x="0" y="0" 幅="560" 身長="380" rx="8" 塗りつぶし="#ふふふふ" /> <タイトルID="parenteral-leachable-thresholds-title">Parenteral leachable thresholds</タイトル> <説明ID="parenteral-leachable-thresholds-desc">PQRI sets a 1.5 µg/day safety concern threshold and a 5 µg/day qualification threshold per organic leachable. Parenteral leachable thresholds. ロリポップデータ: Safety concern 1.5; Qualification 5.Source: PQRI PODP Leachables & Extractables Working Group 2021-10-28.</説明> <テキストx="280.0" y="29" テキストアンカー="真ん中" フォントサイズ="18" フォントの太さ="800" 塗りつぶし="現在の色">Parenteral leachable thresholds</文章> <行 x1="145" y1="298.0" x2="510" y2="298.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="243.0" x2="510" y2="243.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="188.0" x2="510" y2="188.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="133.0" x2="510" y2="133.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="145" y1="78.0" x2="510" y2="78.0" ストローク="現在の色" 不透明度="0.08" /> <テキストx="136.0" y="137.0" テキストアンカー="終わり" フォントサイズ="11" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="136.0" ディ="0">Safety concern</ツパン></文章> <行 x1="145" y1="133.0" x2="254.5" y2="133.0" ストローク="現在の色" 不透明度="0.15" ストローク幅="1" /> <サークルcx="254.5" cy="133.0" r="6" 塗りつぶし="#f97316" /> <テキストx="266.5" y="137.0" フォントサイズ="11" 塗りつぶし="現在の色">1.5</文章> <テキストx="136.0" y="247.0" テキストアンカー="終わり" フォントサイズ="11" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="136.0" ディ="0">Qualification</ツパン></文章> <行 x1="145" y1="243.0" x2="510.0" y2="243.0" ストローク="現在の色" 不透明度="0.15" ストローク幅="1" /> <サークルcx="510.0" cy="243.0" r="6" 塗りつぶし="#38bdf8" /> <テキストx="522.0" y="247.0" フォントサイズ="11" 塗りつぶし="現在の色">5</文章> <テキストx="280.0" y="366" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="私たちの(--チャートミュート, 現在の色)">ソース: PQRI PODP Leachables & Extractables Working Group (2021-10-28)</文章> </SVG> </形>
Request identity, 純度, content and relevant stability evidence for the peptide and finished presentation. Select storage and accelerated conditions from the formulation, intended storage claim and applicable guidance; refrigerated Q1A(R2) conditions are not a universal specification for all peptide-device products.
From the device partner, request injection-force and dose-accuracy testing against ISO 11608-1, which covers single-use needle-based systems incorporating a prefilled syringe (ISO 11608-1:2022), the extractables and leachables package, container closure integrity results, and autoinjector human factors testing with representative users and the final interface. FDAの 2016 human factors guidance addresses human factors studies for combination products, describing the types of studies and recommendations for their timing (FDA human factors guidance).
Do not treat bioequivalence alone as device readiness, do not lock a platform before the container-closure risk assessment is written, and do not read a draft guidance as a requirement. Industry practice reported to us, not documented in guidance, sets device strategy by pre-IND or early Phase 2 and a commercial-intent platform by end of Phase 2.
Ask your peptide partner for the lot-level data package before you lock a device format. Polypeptid Manufacturer
How we apply this at MOL Changes, the publisher of this guide. Our custom peptide synthesis supplies lot-specific material at stated purity, mgからkgまで, with HPLC and MS testing, which covers the identity and purity data you request from a peptide partner. It does not establish device performance, stability in the container, or regulatory acceptance; those you still verify with your device partner and your own studies.
よくある質問
Does the ZILBRYSQ autoinjector approval mean my peptide needs an autoinjector?
いいえ. The approval adds an administration option alongside the existing prefilled syringe for one product in one indication (UCB’s approval announcement). Whether your program needs a device depends on dose volume, viscosity and user population, not on a competitor’s filing.
Is a certificate of analysis enough to support a device submission?
It supports the drug-substance portion only. A specification under ICH Q6B confirms quality and does not characterize delivery performance, and device constituent parts carry separate expectations for glide force, break-loose force and seal integrity (I Q6B).
How early should device work start relative to formulation lock?
The sources do not establish a documented timing standard. What they do show is that container contact can change product quality at fixed formulation, as the epoetin alfa fill-volume comparison demonstrates, so the container-closure risk assessment belongs before the format is fixed rather than after (Seidl et al.).
Does ICH Q3E apply to my combination product today?
Distinguish draft guidance from adopted requirements. Check the current ICH Q3E and regional implementation status when setting the extractables-and-leachables plan; a forecast implementation date is not a binding deadline.
結論
The ZILBRYSQ approval is best read as a demonstration of where the evidence actually lives. The molecule did not change; the container, the device interface and the user interface did, and the supporting package was bioequivalence, usability and human factors data rather than a new purity specification.
That reframes what a peptide partner owes you. Lot-specific identity and purity, a stability package under ICH Q1A(R2), and a clear statement of pH and buffer system are things a synthesis partner can supply and a device partner cannot. Extractables and leachables results, container closure integrity, force measurements and human factors validation belong to the device side, and no peptide certificate substitutes for them.
The practical next step is to map your current data package against that split before any format discussion begins. Where the peptide side is complete and the device side is empty, you know which conversation to have next, and with whom.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Service ranges and capability statements are supplier claims; availability and performance for a specific construct require project-specific evidence.
